ANDA 65441, held by Acs Dobfar. Cefepime Hydrochloride.
As of Nov 16, 2026, ANDA 65441 (Cefepime Hydrochloride), held by Acs Dobfar, was first approved by FDA on Mar 20, 2008, with 8 approved supplements and 0 published complete response letters.
Cefepime for injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia. Empiric therapy for febrile neutropenic patients. Uncomplicated and complicated urinary tract infections (including pyelonephritis). Uncomplicated skin and skin structure infections. Complicated intra-abdominal infections (used in combination with metronidazole) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 20, 2008 | Original application | Approved | None posted |
| Cefepime HydrochlorideEQ 1GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
| Cefepime HydrochlorideEQ 2GM BASE/VIAL · injectable;injection | Cefepime Hydrochloride | Rx |
| Jan 3, 2022 | Supplement 26Labeling · Standard review | Approved | None posted |
| May 25, 2020 | Supplement 16Labeling · Standard review | Approved | None posted |
| May 25, 2020 | Supplement 18Labeling · Standard review | Approved | None posted |
| May 25, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| May 25, 2020 | Supplement 20Labeling · Standard review | Approved | None posted |
| May 25, 2020 | Supplement 21Labeling · Standard review | Approved | None posted |
| Mar 26, 2013 | Supplement 14Labeling · Standard review | Approved | None posted |
| Sep 29, 2011 | Supplement 7Labeling | Approved | None posted |
| Mar 20, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters